Gupta Rohit Kumar, Verma Rajeev, Verma Manisha, Mukherjee Anirudh, Kumar Pramod, Meena Mahendra Kumar, Sharma Manu
Department of General Medicine, All India Institute of Medical Sciences, Raebareli, Uttar Pradesh, India.
Department of General Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India.
J Family Med Prim Care. 2025 Jun;14(6):2113-2118. doi: 10.4103/jfmpc.jfmpc_1349_24. Epub 2025 Jun 30.
The major goal of this study was to analyse the influence of levothyroxine medication on serum lipid levels in individuals with hypothyroidism, as well as its efficacy in controlling dyslipidemia caused by thyroid hormone deficiencies. This method provides a complete assessment of therapy efficacy and aids in identifying factors that may influence treatment results.
This prospective observational study, conducted from September 2019 to October 2020 at Shri Shiv Prasad Gupt Divisional District Hospital in Varanasi, India, included 150 patients with newly diagnosed hypothyroidism. A predesigned proforma was used in the study to collect demographic and medical history information. The data were analysed using SPSS version 23.
The study of 150 newly diagnosed hypothyroidism patients, predominantly aged 31-40 years and with a significant female predominance (95.4%), found a notable age and gender distribution in subclinical versus overt hypothyroidism. Subclinical cases were all female and concentrated in the 31-40 age group, while overt hypothyroidism was more evenly distributed, with a higher prevalence in the same age group and extending to older ages. TSH levels were significantly higher in overt hypothyroidism (45.1 ± 30.4 μU/mL) compared to subclinical hypothyroidism (8.6 ± 0.82 μU/mL, < 0.01), reflecting more severe thyroid dysfunction in overt cases. Levothyroxine therapy improved lipid profiles in both conditions: In subclinical hypothyroidism, total cholesterol and triglycerides decreased and HDL increased; in overt hypothyroidism, total cholesterol, triglycerides, and LDL decreased, while HDL increased significantly. Levothyroxine also effectively normalized TSH levels in both subclinical (8.6 ± 0.8 μU/mL to 2.9 ± 1.33 μU/mL) and overt hypothyroidism (45.1 ± 30.4 μU/mL to 3.5 ± 1.1 μU/mL), demonstrating its efficacy in managing thyroid function and associated dyslipidemia.
The study found that levothyroxine therapy significantly improved lipid profiles and reduced TSH levels in both subclinical and overt hypothyroidism. Despite these positive outcomes, the small sample size and short duration suggest the need for further research with a larger cohort and longer follow-up to validate and expand on these findings.
本研究的主要目的是分析左甲状腺素药物对甲状腺功能减退患者血清脂质水平的影响,以及其在控制甲状腺激素缺乏引起的血脂异常方面的疗效。该方法可全面评估治疗效果,并有助于识别可能影响治疗结果的因素。
本前瞻性观察性研究于2019年9月至2020年10月在印度瓦拉纳西的Shri Shiv Prasad Gupt分区医院进行,纳入了150例新诊断的甲状腺功能减退患者。研究中使用预先设计的表格收集人口统计学和病史信息。数据使用SPSS 23版进行分析。
对150例新诊断的甲状腺功能减退患者的研究发现,主要为31 - 40岁,女性占比显著(95.4%),亚临床甲状腺功能减退与显性甲状腺功能减退在年龄和性别分布上存在显著差异。亚临床病例均为女性,集中在31 - 40岁年龄组,而显性甲状腺功能减退分布更均匀,在同一年龄组患病率更高且延伸至老年。显性甲状腺功能减退患者的促甲状腺激素(TSH)水平(45.1±30.4 μU/mL)显著高于亚临床甲状腺功能减退患者(8.6±0.82 μU/mL,<0.01),反映出显性病例的甲状腺功能障碍更严重。左甲状腺素治疗在两种情况下均改善了血脂谱:在亚临床甲状腺功能减退中,总胆固醇和甘油三酯降低,高密度脂蛋白(HDL)升高;在显性甲状腺功能减退中,总胆固醇、甘油三酯和低密度脂蛋白(LDL)降低,而HDL显著升高。左甲状腺素还有效使亚临床(从8.6±0.8 μU/mL降至2.9±1.33 μU/mL)和显性甲状腺功能减退(从45.1±30.4 μU/mL降至3.5±1.1 μU/mL)患者的TSH水平正常化,证明了其在管理甲状腺功能及相关血脂异常方面的疗效。
研究发现,左甲状腺素治疗在亚临床和显性甲状腺功能减退中均显著改善了血脂谱并降低了TSH水平。尽管有这些积极结果,但样本量小和随访时间短表明需要进一步开展更大样本队列和更长随访时间的研究,以验证和扩展这些发现。